Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of subcutaneous ALX-0061 in rheumatoid arthritis
2014-003034-42Phase 2Completed
- Sponsor
- Ablynx
- Start
- Mar 2015
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vobarilizumab in rheumatoid arthritis (RA), sponsored by Ablynx. Primary endpoints: ACR20 response over time, ACR50 response over time and 1 more. Started Mar 2015; status: completed.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-003034-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003034-42.